Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Retained Earnings: 2019-2025

Historic Retained Earnings for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to -$735.7 million.

  • 4D Molecular Therapeutics' Retained Earnings fell 39.73% to -$735.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$735.7 million, marking a year-over-year decrease of 39.73%. This contributed to the annual value of -$576.2 million for FY2024, which is 38.73% down from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Retained Earnings of -$735.7 million as of Q3 2025, which was down 8.38% from -$678.8 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Retained Earnings high stood at -$152.1 million for Q1 2021, and its period low was -$735.7 million during Q3 2025.
  • Its 3-year average for Retained Earnings is -$507.8 million, with a median of -$482.7 million in 2024.
  • Data for 4D Molecular Therapeutics' Retained Earnings shows a maximum YoY slumped of 63.69% (in 2022) over the last 5 years.
  • Over the past 5 years, 4D Molecular Therapeutics' Retained Earnings (Quarterly) stood at -$207.0 million in 2021, then plummeted by 51.93% to -$314.5 million in 2022, then tumbled by 32.06% to -$415.3 million in 2023, then slumped by 38.73% to -$576.2 million in 2024, then plummeted by 39.73% to -$735.7 million in 2025.
  • Its Retained Earnings was -$735.7 million in Q3 2025, compared to -$678.8 million in Q2 2025 and -$624.2 million in Q1 2025.